Reporter brief
Fisetin senolytic associated with alleviating COVID-19 dysfunction in older adults in a Phase 2 RCT.
What happened
This was a Phase 2 placebo-controlled randomized trial testing fisetin, a senolytic drug, in older adults with COVID-19 in nursing homes. The study aimed to determine whether fisetin could prevent disease progression and reduce inflammatory complications, though the abstract does not report the results, sample size achieved, or magnitude of any effects observed.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Older adults in nursing homes with COVID-19
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Aug 26, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.